Stockreport

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

Annovis Bio, Inc.  (ANVS) 
PDF MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative [Read more]